AVT Plasma (ASX:AVT) has suspended trading in its shares, following a board decision to wind up the company and appoint a provisional liquidator.

Producing products from human blood plasma is a lucrative business and the Chinese market provides a significant long-term opportunity, AVT Plasma's CEO tells Ruth Beran.

Australia's biotechnology industry has had its best performing year since the halcyon days of the 1999-2000 tech boom, with both Intersuisse and Southern Cross Equities reporting a 24 per cent rise in their biotechnology indices to the end of the financial year, compared to the 18 per cent rise seen in the ASX's All Ordinaries Index.